Admescope

Executive Summary

Admescope is a preclinical contract research organization (CRO) headquartered in Oulu, Finland, specializing in ADME-Tox (Absorption, Distribution, Metabolism, Excretion, and Toxicity) services for drug discovery and development. Since 2020, the company has operated as part of the Symeres organization, offering integrated drug discovery capabilities. Admescope provides tailored services for all drug modalities, including small molecules, peptides, oligonucleotides, antibodies, and ADCs, with expertise in drug metabolism, drug interactions, pharmacokinetics, and quantitative bioanalysis. The company serves a global client base of pharmaceutical and biotechnology firms, leveraging its specialized facilities and scientific expertise to accelerate drug development timelines. By being part of a larger integrated drug discovery network, Admescope benefits from cross-referrals and expanded service offerings, positioning itself as a key partner in the preclinical stage of drug development.

Upcoming Catalysts (preview)

• Q4 2026Expansion of Service Offerings to Include New Modalities (e.g., PROTACs or mRNA)70% success
• 2027Major Partnership or Multi-Year Contract with Top 20 Pharma Company40% success
• Q2 2027Investment in New Laboratory Capacity or Automation to Increase Throughput50% success